These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11562275)

  • 21. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
    Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models.
    Liu M; Bishop WR; Nielsen LL; Bryant MS; Kirschmeier P
    Methods Enzymol; 2001; 333():306-18. PubMed ID: 11400347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity.
    Dinsmore CJ; Bell IM
    Curr Top Med Chem; 2003; 3(10):1075-93. PubMed ID: 12769709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation.
    Bishop WR; Kirschmeier P; Baum C
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S96-104. PubMed ID: 14508086
    [No Abstract]   [Full Text] [Related]  

  • 25. Lonafarnib in cancer therapy.
    Morgillo F; Lee HY
    Expert Opin Investig Drugs; 2006 Jun; 15(6):709-19. PubMed ID: 16732721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
    Appels NM; van Maanen MJ; Rosing H; Schellens JH; Beijnen JH
    Rapid Commun Mass Spectrom; 2005; 19(15):2187-92. PubMed ID: 15996016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.
    Taveras AG; Deskus J; Chao J; Vaccaro CJ; Njoroge FG; Vibulbhan B; Pinto P; Remiszewski S; del Rosario J; Doll RJ; Alvarez C; Lalwani T; Mallams AK; Rossman RR; Afonso A; Girijavallabhan VM; Ganguly AK; Pramanik B; Heimark L; Bishop WR; Wang L; Kirschmeier P; James L; Carr D; Liu M
    J Med Chem; 1999 Jul; 42(14):2651-61. PubMed ID: 10411485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
    Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
    Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777.
    Wright J; Blatner GL; Cheson BD
    Oncology (Williston Park); 1999 Nov; 13(11):1527, 1530, 1533. PubMed ID: 10581601
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular biological design of novel antineoplastic therapies.
    Vulfovich M; Saba N
    Expert Opin Investig Drugs; 2004 Jun; 13(6):577-607. PubMed ID: 15174947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
    Thomas X; Elhamri M
    Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
    Bruzek LM; Poynter JN; Kaufmann SH; Adjei AA
    Mol Pharmacol; 2005 Aug; 68(2):477-86. PubMed ID: 15901852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.
    Taveras AG; Aki C; Chao J; Doll RJ; Lalwani T; Girijavallabhan V; Strickland CL; Windsor WT; Weber P; Hollinger F; Snow M; Patton R; Kirschmeier P; James L; Liu M; Nomeir A
    J Med Chem; 2002 Aug; 45(18):3854-64. PubMed ID: 12190309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Farnesyltransferase inhibitors.
    Adjei AA
    Cancer Chemother Biol Response Modif; 2005; 22():123-33. PubMed ID: 16110610
    [No Abstract]   [Full Text] [Related]  

  • 39. From bench top to bedside.
    Barinaga M
    Science; 1997 Nov; 278(5340):1036-9. PubMed ID: 9381201
    [No Abstract]   [Full Text] [Related]  

  • 40. Potent and selective farnesyl transferase inhibitors.
    Millet R; Domarkas J; Houssin R; Gilleron P; Goossens JF; Chavatte P; Logé C; Pommery N; Pommery J; Hénichart JP
    J Med Chem; 2004 Dec; 47(27):6812-20. PubMed ID: 15615530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.